IL1B and breast cancer: In breast cancer, a variety of drugs are currently used in clinical practice to target the IL-1 signaling pathway, including anakinra (Nbib1802970), the standard of care used for phase I metastatic breast cancer, and PDR001 (Nbib2900664), in combination with CJM112, EGF816, Ilaris (canakinumab), or Mekinist (trametinib) used for triple-negative phase I and phase II breast cancer [262].